[HTML][HTML] Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - Elsevier
Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
[引用][C] Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T KATAYAMA - J Thorac Oncol, 2009 - cir.nii.ac.jp
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung
adenocarcinoma who showed initial good response to gefitinib | CiNii Research CiNii 国立 …
adenocarcinoma who showed initial good response to gefitinib | CiNii Research CiNii 国立 …
[PDF][PDF] Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
T Katayama, J Shimizu, K Suda… - Journal of Thoracic …, 2009 - scholar.archive.org
Results: All seven patients had EGFR mutations in their primary tumors except one patient.
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T Katayama, J Shimizu, K Suda… - Journal of thoracic …, 2009 - pubmed.ncbi.nlm.nih.gov
Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
[PDF][PDF] Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - core.ac.uk
Results: All seven patients had EGFR mutations in their primary tumors except one patient.
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - europepmc.org
Results All seven patients had EGFR mutations in their primary tumors except one patient.
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
The median interval between gefitinib withdrawal and erlotinib administration was 5 days …
[HTML][HTML] Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - jto.org
Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
[引用][C] Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T KATAYAMA - J Thorac Oncol, 2009 - cir.nii.ac.jp
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung
adenocarcinoma who showed initial good response to gefitinib | CiNii Research CiNii 国立 …
adenocarcinoma who showed initial good response to gefitinib | CiNii Research CiNii 国立 …